Detalhe da pesquisa
1.
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
Br J Haematol
; 189(5): 853-859, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32064595
2.
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
Br J Haematol
; 184(3): 392-396, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30338509
3.
Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
Blood
; 138(22): 2290-2293, 2021 12 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34297829
4.
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
Blood
; 138(25): 2727-2730, 2021 12 23.
Artigo
Inglês
| MEDLINE | ID: mdl-34587233
5.
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia.
Haematologica
; 107(1): 334-337, 2022 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34647439
6.
ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia.
Br J Haematol
; 190(6): e346-e349, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32579248
7.
Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients.
Cancer Immunol Immunother
; 64(2): 201-11, 2015 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-25341808
8.
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.
Haematologica
; 106(5): 1500-1503, 2020 10 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33054124
9.
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.
Br J Haematol
; 185(1): 156-159, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29785734
10.
Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation.
J Clin Med
; 11(19)2022 Sep 23.
Artigo
Inglês
| MEDLINE | ID: mdl-36233461
11.
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia.
Front Oncol
; 11: 637186, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33937038
12.
The antileukemic potential of natural killer cells.
Immunotherapy
; 8(4): 425-34, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-26973124
13.
Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia.
Oncotarget
; 7(15): 20520-31, 2016 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-26943037
14.
A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.
Blood Transfus
; 13(3): 464-71, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25761309